Evidence guide

Sermorelin Dosage

Historical Geref protocols and small Sermorelin studies describe regulated clinical contexts. They do not validate self-directed dosing for research-vendor vials.

Regulatory history matters

Sermorelin was previously approved as Geref for a defined pediatric indication.

Current products differ

A research-vendor vial is not established as the former approved product.

Adult evidence is limited

Adult studies are small and rely heavily on surrogate outcomes.

What historical evidence establishes

The former Geref program documented a prescription-drug formulation, defined indications, and supervised protocols. The approval was later withdrawn after commercial discontinuation, not because of a finding that the drug was unsafe or ineffective.

Why that is not a research-vial schedule

Product identity and formulation equivalence have not been established.
The historical indication and study population may not match the current query.
Hormone-axis evaluation and contraindications require clinical context.